Status:
COMPLETED
Clinical Evaluation of the Efficacy of a Dietary Supplement Claiming Anti-aging Properties and UV-protection
Lead Sponsor:
Seppic
Conditions:
Healthy Volunteers
Eligibility:
FEMALE
35-65 years
Phase:
NA
Brief Summary
The study aims to assess the anti-aging and photoprotective efficacy of two active concentrations of a food supplement composed of Coriander Seed Oil (CSO).
Detailed Description
A double blind, parallel groups, placebo-controlled study is carried out on 90 female subjects aged between 35 and 65 years old with visible Crow's feet wrinkles and mild to moderate skin slackness. ...
Eligibility Criteria
Inclusion
- Healthy female subjects
- Caucasian ethnicity
- Age between 35 and 65 years old (extremes included)
- Phototype I to III (with all skin types without any specific repartition)
- Visible Crow's feet wrinkles (\> 2 according to Skin Aging Atlas - Caucasian Type - Bazin Roland) and mild to moderate skin slackness at cheek level (grade 1-3 - internal clinical scale)
- Subjects who have not been recently involved in any other similar study (at least 1 month of wash-out)
- Subjects registered with health social security or health social insurance
- Subjects having signed the Informed Consent Form (ICF) and Privacy Policy for their participation in the study and a photograph authorization
- Subjects able to understand the language used in the investigation center and the information given
- Subjects able to comply with the protocol and follow protocol constraints and specific requirements
- Willingness to use during all the study period only the product to be tested
- Willingness not to use similar products that could interfere with the expected product effect to be tested (e.g. with antiaging or soothing or UV protection efficacy)
- Willingness to not vary the normal daily routine (i.e. lifestyle, physical activity, diet etc.)
- Subjects under effective contraception (oral/not oral) if women of childbearing potential; not expected to be changed during the trial
- Subjects who have not sun exposure (both natural or artificial) for at least two months
- Subjects who accept not to expose in intensive way to UV rays during the whole study duration
- Subjects who have not been involved in any sun test (for SPF evaluation) or tests that provide skin irradiation since less than two months
Exclusion
- Subject is taking part or planning to participate to another clinical study in the same or in another investigation center
- Subject who is deprived of freedom by administrative or legal decision or under guardianship
- Subject admitted in a sanitary or social facilities
- Subject who is planning an hospitalization during the study
- Subjects under treatment with food supplements which could interfere with the functionality of the product under study
- Subject breastfeeding, pregnant or not willing to take necessary precautions to avoid pregnancy during the study (if women of childbearing potential)
- Subject has started or changed estrogen-progesterone contraception or hormonal treatment, within the 3 months prior to the study or foreseeing it for the duration of the study
- Subject having an acute, chronic or progressive illness liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
- Subjects under radiotherapy, chemotherapy at any time
- Subject having a skin condition liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
- Pharmacological treatments (topic or systemic) known to interfere with skin metabolism/physiology
- Subjects under locally pharmacological/non-pharmacological treatment applied on the skin area monitored during the test
- Subject with known or suspected sensitization to one or more test formulation ingredients
- Subjects considered as not adequate to participate to the study by the investigator
- Adult protected by law (under control or hospitalized in public or private institutions for reasons other than research, or incarcerated)
- Subjects not able to communicate or cooperate with the investigator for problems related to language, mental retardation or impaired brain function
Key Trial Info
Start Date :
September 25 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 27 2025
Estimated Enrollment :
99 Patients enrolled
Trial Details
Trial ID
NCT06571409
Start Date
September 25 2024
End Date
January 27 2025
Last Update
January 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Complife Italia S.r.l
San Martino Siccomario, Italy, 27028